Exploration of an Prognostic Signature Related to Endoplasmic Reticulum Stress in Colorectal Adenocarcinoma and Their Response Targeting Immunotherapy

被引:0
作者
Xu, Yu [1 ]
Xie, Yang-Mei [2 ]
Sun, Wen-Sha [3 ]
Zi, Rong [2 ]
Lu, Hong-Qiao [2 ]
Xiao, Le [2 ]
Gong, Kun-Mei [2 ]
Guo, Shi-Kui [2 ]
机构
[1] Panzhihua Cent Hosp, Panzhihua, Sichuan, Peoples R China
[2] Kunming Univ Sci & Technol, Affiliated Hosp, Jinbi Rd, Kunming 650500, Yunnan, Peoples R China
[3] Yunnan Univ Tradit Chinese Med, Affiliated Hosp 1, Kunming, Yunnan, Peoples R China
关键词
colorectal adenocarcinoma; endoplasmic reticulum stress; risk score; prognostic model;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Endoplasmic reticulum (ER) stress plays a pro-apoptotic role in colorectal adenocarcinoma (COAD). This study aimed to develop a novel ER-stress-related prognostic risk model for COAD and provide support for COAD cohorts with different risk score responses to immune checkpoint inhibitor therapies. Methods: TCGA-COAD and GSE39582 were included in this prospective study. Univariate and multivariate Cox analyses were performed to identify prognostic ER stress-related genes (ERSGs). Accordingly, the immune infiltration landscape and immunotherapy response in different risk groups were assessed. Finally, the expression of prognostic genes in 10 normal and 10 COAD tissue samples was verified using reverse transcription-quantitative polymerase chain reaction. Results: Eight prognostic genes were selected to establish an ERSG-based signature in the training set of the TCGA-COAD cohort. The accuracy of this was confirmed using a testing set of TCGA-COAD and GSE39582 cohorts. Gene set variation analysis indicated that differential functionality in high-low-risk groups was related to immune-related pathways. Corresponding to this, CD36, TIMP1, and PTGIS were significantly associated with 19 immune cells with distinct proportions between the different risk groups, such as central memory CD4T cells and central memory CD8T cells. Moreover, the risk score was considered effective for predicting the clinical response to immunotherapy, and the immunotherapy response was significantly and negatively correlated with the risk score of individuals with COAD. Furthermore, the immune checkpoint inhibitor treatment was less effective in the high-risk group, where the expression levels of PD-L1 and tumor immune dysfunction and exclusion scores in the high-risk group were significantly increased. Finally, the experimental results demonstrated that the expression trends of prognostic genes in clinical samples were consistent with the results from public databases. Conclusion: Our study established a novel risk signature to predict the COAD prognosis of patients and provide theoretical support for the clinical treatment of COAD.
引用
收藏
页数:18
相关论文
共 55 条
[1]   Therapeutic Dilemma Prognostic Factors and Outcome for Neuroendocrine Tumors of the Cervix [J].
Abdallah, Reem ;
Bush, Stephen H. ;
Chon, Hye Sook ;
Apte, Sachin M. ;
Wenham, Robert M. ;
Shahzad, Mian M. K. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 (03) :553-560
[2]   OCEANS: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Chemotherapy With or Without Bevacizumab in Patients With Platinum-Sensitive Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer [J].
Aghajanian, Carol ;
Blank, Stephanie V. ;
Goff, Barbara A. ;
Judson, Patricia L. ;
Teneriello, Michael G. ;
Husain, Amreen ;
Sovak, Mika A. ;
Yi, Jing ;
Nycum, Lawrence R. .
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) :2039-2045
[3]   Maintenance bevacizumab-pemetrexed after first-line cisplatin-pemetrexed-bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial [J].
Barlesi, F. ;
Scherpereel, A. ;
Gorbunova, V. ;
Gervais, R. ;
Vikstrom, A. ;
Chouaid, C. ;
Chella, A. ;
Kim, J. H. ;
Ahn, M. J. ;
Reck, M. ;
Pazzola, A. ;
Kim, H. T. ;
Aerts, J. G. ;
Morando, C. ;
Loundou, A. ;
Groen, H. J. M. ;
Rittmeyer, A. .
ANNALS OF ONCOLOGY, 2014, 25 (05) :1044-1052
[4]   Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial [J].
Bennouna, Jaafar ;
Sastre, Javier ;
Arnold, Dirk ;
Osterlund, Pia ;
Greil, Richard ;
Van Cutsem, Eric ;
von Moos, Roger ;
Maria Vieitez, Jose ;
Bouche, Olivier ;
Borg, Christophe ;
Steffens, Claus-Christoph ;
Alonso-Orduna, Vicente ;
Schlichting, Christoph ;
Reyes-Rivera, Irmarie ;
Bendahmane, Belguendouz ;
Andre, Thierry ;
Kubicka, Stefan .
LANCET ONCOLOGY, 2013, 14 (01) :29-37
[5]   Evaluation of PARP and PDL-1 as potential therapeutic targets for women with high-grade neuroendocrine carcinomas of the cervix [J].
Carroll, Matthew Ryan ;
Ramalingam, Preetha ;
Salvo, Gloria ;
Fujimoto, Junya ;
Solis Soto, Luisa Maren ;
Phoolcharoen, Natacha ;
Hillman, Robert Tyler ;
Cardnell, Robert ;
Byers, Lauren ;
Frumovitz, Michael .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 (09) :1303-1307
[6]   Anti-angiogenesis Revisited: Combination with Immunotherapy in Solid Tumors [J].
Chambers, Alex ;
Kundranda, Madappa ;
Rao, Santosh ;
Mahmoud, Fade ;
Niu, Jiaxin .
CURRENT ONCOLOGY REPORTS, 2021, 23 (09)
[7]   Phase III Trial of Bevacizumab Plus Interferon Alfa-2a in Patients With Metastatic Renal Cell Carcinoma (AVOREN): Final Analysis of Overall Survival [J].
Escudier, Bernard ;
Bellmunt, Joaquim ;
Negrier, Sylvie ;
Bajetta, Emilio ;
Melichar, Bohuslav ;
Bracarda, Sergio ;
Ravaud, Alain ;
Golding, Sophie ;
Jethwa, Sangeeta ;
Sneller, Vesna .
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (13) :2144-2150
[8]   Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas [J].
Fack, Fred ;
Espedal, Heidi ;
Keunen, Olivier ;
Golebiewska, Anna ;
Obad, Nina ;
Harter, Patrick N. ;
Mittelbronn, Michel ;
Baehr, Oliver ;
Weyerbrock, Astrid ;
Stuhr, Linda ;
Miletic, Hrvoje ;
Sakariassen, Per O. ;
Stieber, Daniel ;
Rygh, Cecilie B. ;
Lund-Johansen, Morten ;
Zheng, Liang ;
Gottlieb, Eyal ;
Niclou, Simone P. ;
Bjerkvig, Rolf .
ACTA NEUROPATHOLOGICA, 2015, 129 (01) :115-131
[9]   Combination therapy with topotecan, paclitaxel, and bevacizumab improves progression-free survival in recurrent small cell neuroendocrine carcinoma of the cervix [J].
Frumovitz, M. ;
Munsell, M. F. ;
Burzawa, J. K. ;
Byers, L. A. ;
Ramalingam, P. ;
Brown, J. ;
Coleman, R. L. .
GYNECOLOGIC ONCOLOGY, 2017, 144 (01) :46-50
[10]   Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract [J].
Frumovitz, Michael ;
Westin, Shannon N. ;
Salvo, Gloria ;
Zarifa, Abdulrazzak ;
Xu, Mingxuan ;
Yap, Timothy A. ;
Rodon, Ahnert J. ;
Karp, Daniel D. ;
Abonofal, Abdulrahman ;
Jazaeri, Amir A. ;
Naing, Aung .
GYNECOLOGIC ONCOLOGY, 2020, 158 (03) :570-575